[go: up one dir, main page]

Racca et al., 1997 - Google Patents

Growth inhibition of DMBA-induced rat mammary carcinomas by UK 114

Racca et al., 1997

Document ID
2003770636594407817
Author
Racca S
Carlo F
Bartorelli A
Bussolati B
Bussolati G
Publication year
Publication venue
Virchows Archiv

External Links

Snippet

A perchloric acid-soluble protein extracted from goat liver and designated as UK 114 is known to be expressed over the cell membrane of (some) human cancer cell lines. This protein is antigenic, and specific antibodies elicit complement-dependent cytolysis of …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer

Similar Documents

Publication Publication Date Title
Takahashi et al. Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated α-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen
Yi et al. Corneal epithelial tight junctions and their response to lipopolysaccharide challenge
Son et al. Depressed natural killer cell activity in patients with hepatocellular carcinoma in vitro effects of interferon and levamisole
EP1350085B1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
CN100457781C (en) Anti-cancer antibodies
JP2003508355A (en) Surface glycoproteins of ovarian cancer cells and myeloma cells, antibodies thereto and uses thereof
JP3213942B2 (en) Polypeptide substances useful for human therapy
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
Chism et al. Immunogenicity of oncofetal antigens: a review
Haimoto et al. Immunohistochemical study of so-called sclerosing haemangioma of the lung
Racca et al. Growth inhibition of DMBA-induced rat mammary carcinomas by UK 114
Öberg et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity
Bergeron et al. Immunocytochemical study of progesterone receptors in hyperplastic and neoplastic endometrial tissues
AU617295B2 (en) Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
Drexhage et al. Dendritic cells in tumor growth and endocrine diseases
US7311906B2 (en) Anti-viral activity of an anti-thymidine kinase monoclonal antibody
US5104652A (en) Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2
Ito et al. Specificity and immunobiological properties of monoclonal antibody IMH2, established after immunization with Leb/Lea glycosphingolipid, a novel extended type 1 chain antigen
EP1141019B1 (en) Substance for producing highly effective anti-tumour medicaments and corresponding method
Harris et al. The measurement of leukocyte subsets in the peripheral blood of cancer patients with solid tumors using monoclonal antibody reagents
Kuramoto et al. In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG
Hanai et al. Distribution of a squamous cell lung carcinoma-associated antigen, KA-32, in human tissues and sera defined by monoclonal antibody KM-32
EP0938329A1 (en) Immunogenic tlp composition
Soergel et al. The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma
EP0681480B1 (en) Recognin vaccines